Joint Meeting of the

CDER Psychopharmacologic Drugs Advisory Committee &

FDA Pediatric Advisory Committee

September 13-14, 2004

CONSULTANTS AND GUESTS

Special Government Employee (SGE) Consultants (voting)

Norman Fost, M.D., M.P.H.

Professor of Pediatrics and Bioethics

University of Wisconsin Medical School

600 Highland Avenue

Madison, Wisconsin 53792

Charles E. Irwin, Jr., M.D.

Pediatrics/ Adolescent Medicine

University of California, San Francisco: Laurel

3333 California Street, Suite 245

San Francisco, California 94143-0503

Laurel K. Leslie, M.D., F.A.A.P.

Pediatrician/Research Scientist

Child & Adolescent Services Research Center

C/o Children’s Hospital

3020 Children’s Way, MC5033

San Diego, California 92123

 

 

Steven Ebert, Pharm. D. (Consumer Representative)

Department of Pharmacy

Meriter Hospital

202 South Park Street

Madison, Wisconsin 53715

James M. Perrin, M.D.

Center for Child and Adolescent Health Policy

50 Staniford Street, Suite 901

Massachusetts General Hospital for Children

Boston, Massachusetts 02114

Cynthia R. Pfeffer, M.D.

Professor of Psychiatry

Weill Medical of Cornell University

New York Presbyterian Hospital

21 Blooming Dale Road

White Plains, New York 10605

 

SGE Patient Representative (voting)

Gail W. Griffith, Washington, D.C.

 

Guest Speakers (non-voting)

Kelly Posner, Ph.D.

Department of Child Psychiatry

New York State Psychiatric Institute

1051 Riverside Drive

New York, New York 10032

 

John March, M.D., M.P.H.

Department of Psychiatry & Behavioral Sciences

Duke Child & Family Study Center

718 Rutherford Street, Room 132

Durham, North Carolina 27710

Guests (non-voting)

Samuel Maldonado, M.D., M.P.H.

(Industry Representative)

920 Route 202 South

Raritan, New Jersey 08869

 

Barbara Stanley, Ph.D

Department of Child Psychiatry

New York State Psychiatric Institute

1051 Riverside Drive

New York, New York 10032

Madelyn Gould, Ph.D., M.P.H.

Department of Child Psychiatry

New York State Psychiatric Institute

1051 Riverside Drive

New York, New York 10032

FDA Participants at the Table (non-voting)

Robert Temple, M.D.

Director, Office of Drug Evaluation I, CDER

Russell G. Katz, M.D.

Director

Division of Neuropharmacological Drug Products, CDER

Thomas Laughren, M.D.

Team Leader

Division of Neuropharmacological Drug Products, CDER

 

 

M. Dianne Murphy, M.D.

Director, Office of Pediatric Therapeutics,

Office of the Commissioner

Anne Trontell, M.D., M.P.H.

Deputy Director, Office of Drug Safety, CDER